文献速递免疫规划

含猪圆环病毒2a和2d型抗原的二价亚单位疫苗效力与免疫持续期评价

Evaluation of the efficacy and duration of immunity of a bivalent subunit vaccine containing porcine circovirus type 2a and type 2d antigen.
PubMed 文献 · Vaccine · 2026-09-12

研究评估含PCV2a和PCV2d抗原的新型 commercial 亚单位疫苗(Ingelvac CircoFLEX® AD)对猪的保护效果。采用剖腹产初乳剥夺猪,随机分为安慰剂对照组和疫苗组,开展六项研究,分别在2周龄、免疫起始和免疫持续期攻击PCV2a或PCV2d。结果显示疫苗组组织耗竭和定植阳性率显著低于对照组,支持该疫苗对两种基因型攻击的效力、免疫起始为接种后2周、免疫持续期为26周。

要点

  • 疫苗对PCV2a和PCV2d攻击均显示效力,2周龄接种可诱导保护。
  • 免疫起始时间为接种后2周,免疫持续期达26周。
  • 六项研究中疫苗组组织阳性率4%–44%,对照组55%–100%,差异显著(P≤0.0031)。

核心结论

  • 含PCV2a和PCV2d抗原的二价亚单位疫苗对两种基因型攻击均有效,免疫起始为2周,持续期26周。

研究设计与样本

  • 六项研究采用剖腹产初乳剥夺猪,按窝区组随机分为安慰剂对照组和疫苗组,分别于2周龄、免疫起始和免疫持续期攻击PCV2a或PCV2d。

主要发现

  • 六项研究中对照组55%–100%的猪组织耗竭和定植阳性,疫苗组仅4%–44%阳性,各研究差异均显著(P≤0.0031)。
  • 结果支持疫苗在2周龄对PCV2a和PCV2d攻击的效力、接种后2周免疫起始及26周免疫持续期。

临床怎么用

  • 可用于2周龄仔猪接种,以预防PCV2a和PCV2d相关疾病,免疫保护期约26周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and is used extensively today. Studies in vaccinated populations across the world indicate a major PCV2 genotype shift towards genotype 2d (PCV2d) becoming the predominant genotype, with genotype PCV2a still being a prevalent genotype. Here we present a series of studies that evaluated a novel commercial subunit vaccine, including both PCV2a and PCV2d antigens, Ingelvac CircoFLEX® AD, to protect pigs against PCV2 associated disease and provide homologous protection against PCV2a or PCV2d. Cesarean-derived, colostrum-deprived pigs were blocked by litter and randomly assigned to Placebo Control and Vaccine groups which received the novel vaccine. Six studies were carried out to determine efficacy at two weeks of age, the onset of immunity, and the duration of immunity after challenge with PCV2a or PCV2d. Across all six studies, 55 to 100% of Control pigs were positive for depletion and colonization while only 4 to 44% of Vaccine pigs were positive for depletion and colonization with statistically significant differences for each study, P ≤ 0.0031. These results support the efficacy of the novel vaccine against challenge by both PCV2a and PCV2d at 2 weeks of age, an onset of immunity of 2 weeks after vaccination, and 26 weeks duration of immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kaiser TJ, Jarrett A, Johnson W, et al. Evaluation of the efficacy and duration of immunity of a bivalent subunit vaccine containing porcine circovirus type 2a and type 2d antigen. Vaccine. 2026. PMID: 42732726. doi:10.1016/j.vaccine.2026.129159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。